Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Photo of Jeremy J. Johnson

Jeremy J. Johnson

Professor, Pharmacy Practice
Assistant Head, Research, Pharmacy Practice
Member, Cancer Center – Translational Oncology Program
Clinical Pharmacist, College of Pharmacy

Related Sites:

About Heading link

Dr. Jeremy Johnson is a Professor at the University of Illinois Chicago (UIC) in the College of Pharmacy with a research program focused on the translational development of experimental therapeutics with a focus on phytochemicals.

Dr. Johnson received his BS in biology from the University of Wisconsin-Stevens Point, his PharmD from the University of Wisconsin-Madison, and his PhD from the University of Wisconsin-Madison in Biomedical Sciences. He received his PharmD and PhD from the University of Wisconsin (UW). During his training at UW he completed an NIH CTSA Fellowship to evaluate natural products for cancer prevention. He is also a licensed pharmacist and is interested in the clinical development of plant extracts and phytochemicals to improve human health.

Research Interests:
Dr. Johnson’s research is focused on the translational development of experimental therapeutics. His primary research area is focused on natural products including phytochemicals in the areas of cancer, fertility and inflammation. He received an R37 NIH MERIT award for his work on the mangosteen fruit (Garcinia mangostana) for prostate cancer prevention. This work has helped described a novel mechanism of xanthones from the mangosteen for promoting degradation of the androgen receptor, a key target in prostate cancer. He has additional projects including the evaluation of rosemary (Salvia rosmarinus) for colitis and breast cancer. Another project is evaluating green tea extract in combination with fertility promoting drugs for women win uterine fibroids in a multi-site clinical trial. He has also has a collaboration evaluating the use of a topical anti-estrogen in women previously diagnosed with breast cancer.

The goal of his research program is to span preclinical research to early phase clinical trials. A variety of experimental techniques are employed that include the isolation of phytochemicals from plants, mechanistic studies using cell free and cell based assays, pharmacokinetics in small animals and humans, in vivo animal models, and the pharmacodynamics of experimental therapeutics in humans. Since 2007, his research has been continuously funded with support from the National Institutes of Health (NIH), the USDA, the American Cancer Society, as well as non-profit organizations. This funding includes pre-clinical and clinical research projects. Dr. Johnson has been invited to present his research at the Pasteur Institute in Paris, University of Vienna, Central South University in China, Hunan Medical University in China, University of Santo Tomas in the Philippines, and Erciyes University in Kayseri, Turkey.

Teaching and Supervision Heading link

PSCI Ph.D. Thesis Research (PSCI 599), 1/8/2024 – 4/26/2024
Pathobiology of Cancer (PATH 511), 1/8/2024 – 4/26/2024
Concentration Research (PMPR 485), 1/8/2024 – 4/26/2024
Undergrad Resrch Pharm Pract (PMPR 380), 8/21/2023 – 12/1/2023
PSCI Ph.D. Thesis Research (PSCI 599), 8/21/2023 – 12/1/2023
PSCI Ph.D. Thesis Research (PSCI 599), 1/9/2023 – 4/28/2023
Special Proj Pharm Sci (PSCI 390), 1/9/2023 – 4/28/2023
Undergrad Resrch Pharm Pract (PMPR 380), 8/22/2022 – 12/2/2022
PDAT 8: Special Topics (PHAR 508), 8/22/2022 – 12/2/2022

Selected Grants

Maribavir Clearance during in vitro Continuous Renal Replacement Therapy, Takeda Pharmaceuticals., 12/12/2023 - 6/1/2025, Obligated Amount: $146513.18; Anticipated Amount: $146513.18

VIDAS® NEPHROCLEARTM CCL14 Diagnostic Accuracy Study, bioMerieux., 6/1/2023 - Present, Obligated Amount: $51000; No Anticipated Amount Set

B3166 : VIDAS� NEPHROCLEARTM CCL14 : Sample Stability Study, Reference number 423961, bioMerieux., 12/9/2021 - 9/15/2024, Obligated Amount: $76998; Anticipated Amount: $76998

Implications of MTHFR Polymorphisms in Women receiving a Combination of Green Tea Extract and Fertility Promoting Drugs on Serum Folate Levels, NIH - NICHD - National Institute of Child Health & Human Development., 9/1/2020 - 8/31/2021, Obligated Amount: $159900; Anticipated Amount: $159900

Increasing the cure fraction in myeloma- a novel strategy to personalize melphalan dosing and overcome DNA repair-mediated resistance, UIC College of Pharmacy., 8/1/2020 - 7/31/2021, Obligated Amount: $25000; No Anticipated Amount Set

, 7/1/2020 - 6/30/2025, No Obligated Amount Set; No Anticipated Amount Set

Use of Carnosic Acid and VivOX4 0 for Breast Cancer Prevention, National Institutes of Health (National Cancer Institute)., 7/1/2020 - 12/30/2024, Obligated Amount: $1683454; Anticipated Amount: $1683454

Pilot Study to Develop and Test a Multiplex Assay for CYP450 Phenotyping in Multiple Myeloma Patients Receiving Bortezomib, Hematology Oncology Pharmacy Association (HOPA)., 3/1/2020 - 1/31/2024, Obligated Amount: $85283; Anticipated Amount: $85283

3/4, University of Illinois at Chicago Clinical Site- Reproductive Medicine Collaborative Consortium: A randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroids, National Institutes of Health (Eunice Kennedy Shriver National Institute of Child Health and Human Development)., 9/26/2019 - 8/31/2024, Obligated Amount: $1730822; Anticipated Amount: $1749905

Selected Publications

Belcher, Rachel, Mashhad, Sara, Dahlquist, Ashley, Johnson, Jeremy James, Dangi, Bikash, Benedetti, Enrico, Benken, Jamie, Benken, Scott T. (2024). Characterizing the Stability of Angiotensin II in 0.9% Sodium Chloride Using High Performance Liquid Chromatography and Liquid Chromatography Tandem Mass Spectrometry. Hospital Pharmacy, 59, (2), 198-201. doi:10.1177/00185787231206525.

Hajirahimkhan, Atieh, Bartom, Elizabeth T, Chandrasekaran, Sriram, Chen, Ruohui, Johnson, Jeremy J, Clare, Susan E, Khan, Seema A. (2024). Abstract 7306: Licochalcone A is an excellent candidate for preventing luminal and non-luminal breast cancers. Cancer Research, 84, (6_Supplement), 7306-7306. doi:10.1158/1538-7445.am2024-7306.

Gurgul, Aleksandra, Khin, Manead, Souliya, Onevilay, Sydara, Kongmany, Burdette, Joanna E, Johnson, Jeremy J, Che, Chun-Tao. (2024). Acetogenins from the Stem of Uvaria rufa and Their Cytotoxic Activity. Journal of Natural Products, 87, (2), 207-216. doi:10.1021/acs.jnatprod.3c00838.

Al-Hendy, Ayman, Segars, James H, Taylor, Hugh S, González, Frank, Siblini, Hiba, Zamah, Musa, Alkelani, Hiba, Singh, Bhuchitra, Flores, Valerie A, Christman, Gregory M, Johnson, Jeremy J, Huang, Hao, Zhang, Heping. (2024). Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) – protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids. BMJ Open, 14, (1), e078989. doi:10.1136/bmjopen-2023-078989.

Gurgul, Aleksandra, Wu, Zhenlong, Han, Kyu-Yeon, Shetye, Gauri, Sydara, Kongmany, Souliya, Onevilay, Johnson, Jeremy J, Che, Chun-Tao. (2023). Polyoxygenated cyclohexene derivatives and other constituents of Uvaria rufa stem. Phytochemistry, 216, 113884. doi:10.1016/j.phytochem.2023.113884.

Gurgul, Aleksandra, Nauman, Mirielle C, Wu, Zhenlong, Shetye, Gauri, Ma, Rui, Youn, Isoo, Souliya, Onevilay, Bisson, Jonathan, Johnson, Jeremy J, Che, Chun-Tao. (2023). Chemical constituents of the stem of Marsypopetalum modestum and their bioactivities. Natural Product Research, 37, (21), 3623-3630. doi:10.1080/14786419.2022.2097229.

Rivera Rodríguez, Rocío, Johnson, Jeremy James. (2023). Terpenes: Modulating anti-inflammatory signaling in inflammatory bowel disease. Pharmacology & Therapeutics, 248, 108456. doi:10.1016/j.pharmthera.2023.108456.

Sweiss, Karen, Patel, Pritesh, Guo, Janet, Kim, Kyeongmin, Hill, Kasey, Abbott, Nicole, Johnson, Jeremy, Irby, Donald, Quigley, John G, Rondelli, Damiano, Harvey, R Donald, Nooka, Ajay K, Dhodapkar, Madhav, Kaufman, Jonathan L, Joseph, Nisha S, Lonial, Sagar, Sborov, Douglas W, Phelps, Mitch A, Hofmeister, Craig C. (2022). Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study). Blood, 140, (Supplement 1), 5988-5990. doi:10.1182/blood-2022-170778.

Nauman, Mirielle C, Johnson, Jeremy J. (2022). The purple mangosteen (Garcinia mangostana): Defining the anticancer potential of selected xanthones. Pharmacological Research, 175, 106032. doi:10.1016/j.phrs.2021.106032.

Professional Leadership

Board Member, 7/1/2022 - Present

Notable Honors

★ 2019, NIH MERIT Award (National Cancer Institute), National Cancer Institute

★ 2015, Hans W. Vahlteich UIC Research Scholar, University of Illinois at Chicago


B.S., University of Wisconsin–Stevens Point, United States, 2001
Pharm.D., University of Wisconsin Hospital and Clinics, United States, 2007
Ph.D., University of Wisconsin School of Medicine and Public Health, United States, 2010

Licensures and Certifications

Registered Pharmacist, Wisconsin Department of Safety and Professional Services, 10/2007 - Present
Registered Pharmacist, Illinois Department of Financial and Professional Regulation, 3/2011 - Present

Selected Presentations

Johnson, Jeremy. (2022 June 22). Pharmacological and Pharmacokinetic properties of rosemary for prostate cancer.. 26th Biannual Pharmacognosy Conference. Ankara Turkey.